Cell reports. Medicine · 2022

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Fendler Annika, Shepherd Scott T C, Au Lewis, Wu Mary, Harvey Ruth, Wilkinson Katalin A, Schmitt Andreas M, Tippu Zayd, Shum Benjamin, Farag Sheima, Rogiers Aljosja, Carlyle Eleanor, Edmonds Kim, Del Rosario Lyra, Lingard Karla, Mangwende Mary, Holt Lucy, Ahmod Hamid, Korteweg Justine, Foley Tara, Barber Taja, Emslie-Henry Andrea, Caulfield-Lynch Niamh, Byrne Fiona, Deng Daqi, Kjaer Svend, Song Ok-Ryul, Queval Christophe J, Kavanagh Caitlin, Wall Emma C, Carr Edward J, Caidan Simon, Gavrielides Mike, MacRae James I, Kelly Gavin, Peat Kema, Kelly Denise, Murra Aida, Kelly Kayleigh, O'Flaherty Molly, Shea Robyn L, Gardner Gail, Murray Darren, Popat Sanjay, Yousaf Nadia, Jhanji Shaman, Tatham Kate, Cunningham David, Van As Nicholas, Young Kate, Furness Andrew J S, Pickering Lisa, Beale Rupert, Swanton Charles, Gandhi Sonia, Gamblin Steve, Bauer David L V, Kassiotis George, Howell Michael, Nicholson Emma, Walker Susanna, Wilkinson Robert J, Larkin James, Turajlic Samra

Аннотация

Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.

Предметные рубрики MeSH

Humans Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine Clinical Studies as Topic COVID-19 COVID-19 Vaccines Immunity Neoplasms SARS-CoV-2

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH